FindMyKOL
Clinical trialNCT04939051RecruitingPhase 2Interventional

Obeticholic Acid for Prevention in Barrett's Esophagus

NCT04939051 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is recruiting participants. It studies Obeticholic acid and Placebo Administration in Barrett Esophagus and Esophageal Adenocarcinoma. The registry lists an enrollment of 30 participants at 8 sites in 1 country. The registry lists a start date of 3 Jan 2024 and a primary completion date of 1 Sept 2027. 2 of its registered investigators have a FindMyKOL profile.

SponsorNational Cancer Institute (NCI) →Enrollment30Barrett EsophagusEsophageal Adenocarcinoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04939051
FieldValue
Registry IDNCT04939051
StatusRecruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorNational Cancer Institute (NCI)
Enrollment30
Registered sites8
Countries1
ConditionsBarrett Esophagus and Esophageal Adenocarcinoma
DrugsObeticholic acid and Placebo Administration
Start3 Jan 2024
Primary completion1 Sept 2027
Study completion1 Sept 2027
Last update posted18 Nov 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to neoplastic progression in Barrett's esophagus. Obeticholic acid has shown anti-cholestatic, anti-inflammatory and anti-fibrotic effects mediated by FXR activation. It down regulates bile acid availability and decreases proinflammatory cytokine production including IL-1beta and TNFalpha in human enterocytes and immune cells. This chain of events reduces the bile acid exposure in esophagus tissue thereby limiting bile acid induced damage and dysplastic progression.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Kansas, United States1 site, 1 recruiting
  • University of Kansas Cancer Center

    Kansas City

    Ajay Bansal
    Recruiting
Michigan, United States1 site, 1 recruiting
Missouri, United States1 site, 1 recruiting
  • Washington University School of Medicine

    St Louis

    Dayna S. Early
    Recruiting
North Carolina, United States1 site, 1 recruiting
  • Unc Lineberger Comprehensive Cancer Center

    Chapel Hill

    Nicholas J. Shaheen
    Recruiting
Ohio, United States4 sites, 2 recruiting
  • Case Western Reserve University

    Cleveland

    Recruiting
  • Cleveland Clinic Foundation

    Cleveland

    Prashanthi Thota
    Recruiting
  • Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

    Cleveland

    Joseph E. Willis
    Not, yet, recruiting
  • University Hospitals Cleveland Medical Center

    Cleveland

    Not, yet, recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichigan: 1 site, 1 recruitingMI1New YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhio: 4 sites, 2 recruitingOH4PennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouri: 1 site, 1 recruitingMO1KentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansas: 1 site, 1 recruitingKS1ArkansasARTennesseeTNNorth Carolina: 1 site, 1 recruitingNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Obeticholic acid →Placebo Administration
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04939051

Each answer restates registry values shown on this page.

What is NCT04939051?

NCT04939051 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies Obeticholic acid and Placebo Administration in Barrett Esophagus and Esophageal Adenocarcinoma.

Is NCT04939051 recruiting?

As of 21 Nov 2026, it is recruiting participants. 6 of its 8 sites list their own status as recruiting.

Who leads NCT04939051?

The registry names Prashanthi Thota (principal investigator, University of Michigan Rogel Cancer Center) as the overall official.

Where does NCT04939051 run?

The registry lists 8 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04939051 study?

The registered drug and biological interventions are Obeticholic acid and Placebo Administration.

When is NCT04939051 expected to complete?

The registry lists a primary completion date of 1 Sept 2027 and a study completion date of 1 Sept 2027. The sponsor last updated the record on 18 Nov 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.